Scancell Holdings plc (LON:SCLP – Get Free Report) shares traded down 17.6% during mid-day trading on Thursday . The company traded as low as GBX 9.90 and last traded at GBX 10.50. Approximately 17,677,387 shares were traded during trading, an increase of 771% from the average session volume of 2,029,101 shares. The stock had previously closed at GBX 12.75.
Scancell Price Performance
The firm’s fifty day moving average price is GBX 19.16 and its 200 day moving average price is GBX 15.13. The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29. The stock has a market cap of £108.97 million, a PE ratio of -19.09 and a beta of 0.74.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Featured Stories
- Five stocks we like better than Scancell
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
- Otis Took Another Guidance Cut—But the Story Isn’t Over
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
